2024
First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Chandana S, Choudhury N, Dowlati A, Chiang A, Garmezy B, Kim J, Byers L, Ahn M, Kim T, Kim Y, Han J, Bar J, Zha J, Henner W, Robinson R, KOHLHAPP F, Hingorani P, Papadopoulos K. First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2024, 42: 3001-3001. DOI: 10.1200/jco.2024.42.16_suppl.3001.Peer-Reviewed Original ResearchSmall cell lung cancerAntibody-drug conjugatesDose escalationNeuroendocrine neoplasmsCentral nervous systemRelapsed/refractory small cell lung cancerApproximate dose-proportional increasesHigh-grade CNS tumorsRecommended phase 2 doseModels of small cell lung cancerHigh-grade neuroendocrine neoplasmsFirst-in-human studyCentral nervous system tumorsClinical benefit rateDose-expansion studyMedian prior linesPhase 2 doseDose-limiting toxicityMaximum tolerated doseDose-proportional increaseCell lung cancerHigh-grade gliomasElimination half-lifeBayesian optimal interval designData cutoff
2020
359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results
Borghaei H, Boyer M, Johnson M, Govindan R, Rodrigues L, Blackhall F, Boosman R, Champiat S, Hummel H, Lai W, Udagawa H, Chiang A, Dowlati A, Hann C, Salgia R, Vokes E, Minocha M, Hashemi-Sadraei N, Shetty A, Smit M, Yang H, Owonikoko T. 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results. Journal For ImmunoTherapy Of Cancer 2020, 8: a384-a384. DOI: 10.1136/jitc-2020-sitc2020.0359.Peer-Reviewed Original ResearchDelta-like ligand 3Small cell lung cancerCytokine release syndromeAdverse eventsImmune therapyPD-1/PD-L1 treatmentDose levelsRefractory small cell lung cancerOngoing phase 1 studiesTreatment-emergent adverse eventsTumor cellsCommon adverse eventsMedian prior linesMedian treatment durationPD-L1 treatmentPlatinum-based regimenAcceptable safety profileDose-proportional increaseFurther dose escalationPhase 1 studyCell lung cancerDuration of responseEthics BoardAnti-tumor activityECOG PS